Fast Track Designation granted for treatment of osteosarcoma Orphan Drug Designation granted for treatment of soft tissue sarcoma Multiple FDA designations underscores the promise of SOT106 and strengthens the program’s potential path to patients First-in-human study of SOT106 on track to be initiated in 2026

Swiss Bioscience selected as OrganTech's preferred strategic partner in Europe for regulatory development, GMP manufacturing, clinical research, and potential commercialization of the conditioned medium technology.

SOTIO Biotech today announced that the first participant has been dosed in its Phase 1/2 CADENCIA-01 clinical trial of SOT109 in colorectal cancer. SOT109 is a potentially best-in-class antibody-drug conjugate exploiting the highly promising target of CDH17 for the treatment of CRC and other gastrointestinal cancers. As the only CDH17-targeting ADC that has been granted U.S. FDA Fast Track Designa

Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE 87% attack rate reduction versus placebo observed in people with HAE Type 1 or Type 2 All secondary efficacy endpoints met with statistical significance Well-tolerated safety profile of deucrictibant XR demonstrated